Abstract
Summary
Hypoglycemia is one of the paraneoplastic syndrome manifestations that arise from primary and secondary liver cancer. Hypoglycemia usually presents in the late stage of the disease and indicates a poor prognosis. This case series displays the characteristics profile of patients with primary and secondary liver cancer who are presented with hypoglycemia in a tertiary referral hospital in Indonesia. The study included 41 liver cancer patients who were presented with hypoglycemia. Hepatocellular carcinoma was diagnosed in 51.2% of patients, metastatic liver disease in 14.6% of patients, and undiagnosed liver cancer in 34.1% of patients. The mean age was 47.7 years with male predominance (65.9%). Jaundice was found in 58.5% and hepatomegaly in 70.7% of patients. The mean (± S.D.) initial blood glucose was 42.15 ± 17.11 mg/dL and the Child–Pugh score was 9.93 ± 2.11. Based on imaging, tumor diameter was 12.6 ± 6.9 cm, multiple (61%), and involving both lobes (61%). Treatments for hypoglycemia included oral/enteral feeding, intravenous dextrose, and steroids. No treatment was given for the cancer because all patients were in an advanced stage. The treatment resulted in 41.5% blood glucose being controlled, 56.1% refractory, and 2.4% persistent. Mortality was 70.7% and in average occurred 5.76 ± 4.99 days after hypoglycemia. The mainstay of treatment in these cases is treating the tumor with cytoreduction. However, it was difficult to do cytoreduction because the tumor was already in an advanced stage. Beneficial supportive treatments for maintaining normal blood glucose are frequent meals, dextrose infusion, steroids, and glucagon.
Learning points
-
Hypoglycemia in liver cancer occurs due to the failure of the liver to fulfill body glucose demand because the liver parenchyma has been largely replaced by the tumor, in addition to the high production of insulin growth factor (IGF).
-
Hypoglycemia is often caused by islet cell and non-islet cell tumors, with a higher occurrence in non-islet cell tumors due to paraneoplastic syndrome and the high metabolic requirements of the tumor.
-
The mainstay of NICTH treatment is treating the tumor with cytoreduction. However, in an advanced stage, cytoreduction therapy is often challenging to conduct. Beneficial supportive treatments for controlling blood glucose are frequent meals, dextrose infusion, and the injection of steroids and glucagon.
-
Steroids play a beneficial role in the treatment of persistent hypoglycemia in hepatocellular carcinoma by stimulating gluconeogenesis and increasing lipolysis. Steroids also have roles in the inhibition of peripheral glucose intake, suppression of big IGF-2 production, and modulation of the GH–IGF axis.
Background
Hypoglycemia is an emergency condition that can be fatal if not detected early and treated immediately. Although most cases of hypoglycemia occur due to diabetes-mellitus-related treatment, hypoglycemia occurrence can also be caused by islet cell and non-islet cell tumors. Patients with non-islet cell tumors have a higher chance of suffering from hypoglycemia due to paraneoplastic syndrome and the high metabolic requirements of the tumor (1). Hepatocellular carcinoma (HCC) is the second most common cause of non-islet cell tumor hypoglycemia (NICTH). In HCC cases, the prevalence of hypoglycemia varies from 4% to 27% (2). Hypoglycemia usually occurs in an advanced stage of the disease where it is attributed to the large size of the tumor. However, several studies reported hypoglycemia as an early presentation of hepatocellular carcinoma (3, 4, 5). Hypoglycemia in advanced hepatocellular carcinoma is associated with poor prognosis (6). The objective of this study is to review the characteristics profile of patients with liver cancer who presented with hypoglycemia.
Case presentation
In this study, we found 41 patients with liver cancer who presented with hypoglycemia. Moreover, 18 patients showed capillary or vein blood glucose level test results below 50 mg/dL at the time of initial hospital admission from July 2017 until February 2021 in Dr Cipto Mangunkusumo National General Hospital, a tertiary referral hospital located in Jakarta, the capital city of Indonesia. We included all patients with liver cancer regardless of the type and etiology. Hypoglycemia was diagnosed based on capillary or vein blood glucose level test results that were below 70 mg/dL. We defined controlled hypoglycemia as a single hypoglycemia event that was successfully corrected after treatment. Meanwhile, persistent hypoglycemia is a prolonged hypoglycemia event despite continuous treatment. Refractory hypoglycemia is described as repetitive hypoglycemia that requires repetitive treatment (1).
Table 1 shows the characteristics of these patients. More than half (65.9%) of the patients were male with a mean age of 47.7 years. Only 4.8% of the patients had type 2 diabetes mellitus. We found that 70.7% of patients had hepatomegaly, 63.4% had ascites, and 58.5% had jaundice. Cirrhosis was found in 36.6% of patients. Hepatocellular carcinoma was confirmed in 51.2% of the patients, metastatic liver disease in 14.6% of the patients, and 34.1% of the patients had an undetermined type of liver cancer. There were no adrenal issues like adrenal metastasis and adrenal insufficiency in this series of patients. Mortality was 70.7% and on average occurred 5.76 ± 4.99 days after hypoglycemia.
Characteristics of the subjects. Data are presented as n (%) or as mean ± s.d.
Characteristics | Values |
---|---|
n | 41 |
Age (years) | 47.7 ± 12.56 |
Sex, male | 27 (65.9) |
Mortality | 29 (70.7) |
14-day mortality | 28 (68.3) |
Mortality after hypoglycemia (days) | 5.76 ± 4.99 |
T2DM | 2 (4.8) |
Physical Examination | |
Jaundice | 24 (58.5) |
Hepatomegaly | 29 (70.7) |
Splenomegaly | 5 (12.2) |
Ascites | 26 (63.4) |
Edema | 14 (34.1) |
Cirrhosis | 15 (36.6) |
Type of liver cancer | |
HCC | 21 (51.2) |
Metastasis | 6 (14.6) |
NHL | 3 (7.3) |
Breast | 1 (2.4) |
Colon | 2 (4.8) |
Undetermined | 14 (34.1) |
Liver nodules | 10 (24.4) |
Liver + pulmonary nodules | 3 (7.3) |
Liver nodules + breast tumor | 1 (2.4) |
Response to the treatment | |
Controlled | 17 (41.5) |
Persistent | 1 (2.4) |
Refractory | 23 (56.1) |
HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NHL, non-Hodgkin lymphoma; T2DM, type 2 diabetes mellitus.
Investigation
Laboratory investigation
The results of the laboratory parameters of the patients are shown in Table 2. The mean initial blood glucose was 42.15 ± 17.11 mg/dL. The median bilirubin level was 4.88 (1.59–15.41) mg/dL. Hepatitis B surface antigen (HBsAg) was reactive in 57.6% of patients, while only 4.9% of patients were reactive for anti-HCV. Child–Pugh score mean was 9.93 ± 2.11.The median creatinine level was 0.90 (0.50–1.80) mg/dL. From the data, we also found that only two patients had reached end-stage renal disease and depended on dialysis.
Laboratory parameters. Data are presented as mean ± s.d., n (%) or as median (IQR).
Characteristics | Values |
---|---|
n | 41 |
Hemoglobin, g/dL | 10.7 ± 2.72 |
Platelet, 103/µL | 299.5 ± 193.67 |
PT, second | 15.6 (13.4–17.9) |
INR, second | 1.40 (1.23–1.72) |
AST, U/L | 279 (173–475) |
ALT, U/L | 65 (36–115) |
Total bilirubin, mg/dL | 4.88 (1.59–15.41) |
Direct bilirubin, mg/dL | 3.65 (0.91–11.37) |
Indirect bilirubin, mg/dL | 1.47 (0.52–3.50) |
Albumin, g/L | 2.56 (2.22–3.13) |
Creatinine, mg/dL | 0.90 (0.50–1.80) |
Initial blood glucose, mg/dL | 42.15 ± 17.11 |
Sodium, meq/L | 129 (125–134) |
HBsAg (+) | 24 (58.5) |
Anti-HCV (+) | 2 (4.9) |
Child–Pugh score | 9.93 ± 2.11 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; INR, international normalized ratio; PT, prothrombin time.
Radiologic characteristics
We included all radiology modalities, including ultrasonography, CT scan, and MRI. The results are summarised in Table 3. Based on various imaging modalities, the mean of the tumor diameter was 12.6 ± 6.9 cm. The majority of the patients had multiple tumors (61%) and had tumors that involved both lobes (61%).
Radiologic characteristics of liver cancer. Data are presented as mean ± s.d. or as n (%).
Characteristics | Total | Controlled | Persistent | Refractory |
---|---|---|---|---|
n | 41 | 17 | 1 | 23 |
Size, cm | 12.6 ± 6.9 | 9.2 ± 6.8 | 7.7 | 16.7 ± 5.4 |
Number of lesions | ||||
Solitary | 3 (7.3) | 1 (5.9) | 1 (100) | 1 (4.3) |
Multiple | 25 (61.0) | 11 (64.7) | 0 (0) | 14 (60.9) |
Diffuse | 13 (31.7) | 5 (29.4) | 0 (0) | 8 (34.8) |
Location | ||||
Right lobe | 16 (39.0) | 5 (29.4) | 1 (100) | 10 (43.5) |
Left lobe | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Both lobes | 25 (61.0) | 12 (70.6) | 0 (0) | 13 (56.5) |
PV thrombus | 8 (19.5) | 1 (5.9) | 0 (0) | 7 (30.4) |
PV, portal vein.
Treatment
Hypoglycemia was treated with a standard treatment protocol, including oral/enteral feeding and intravenous glucose. Intravenous steroids were not routinely given. Only 26.8% of the patients were given steroids based on the consideration of the treating physician. Specific cancer treatment was not given because all the patients were in advanced stages.
Outcome and follow-up
The hypoglycemia treatment resulted in 41.5% of blood glucose being controlled; 56.1% was refractory, and 2.4% was persistent (Table 4).
Response to hypoglycemia treatment. Data are presented as mean ± s.d. or as n (%).
Treatment | Total | Controlled | Persistent | Refractory |
---|---|---|---|---|
Initial blood glucose, mg/dL | 42.15 ± 17.11 | 51.6 ± 13.1 | 17.9 | 36.8 ± 16.7 |
Hypoglycemia treatment | ||||
Feeding + Dx | 30 (73.2) | 15 (88.2) | 0 (0) | 15 (65.2) |
Feeding + Dx + steroid | 11 (26.8) | 2 (11.8) | 1 (100) | 8 (34.8) |
Dx, dextrose.
Discussion
Hypoglycemia in liver cancer occurs due to the failure of the liver to fulfill body glucose demand because the liver parenchyma has been largely replaced by the tumor, in addition to the high production of insulin growth factor (IGF). Non-islet cell tumor hypoglycemia (NICTH) is divided into two types, i.e. type A and type B (7). Type A is often seen in advanced stages, when large-size tumors infiltrate liver parenchyma and consume high amounts of glucose in malnourished patients who already have depleted glycogen storage and defective gluconeogenesis (8). Type A NICTH usually occurs in late-stage disease when liver parenchymal damage is massive, such as in cirrhotic liver. Liver damage contributes to low levels of insulin and C-peptide, and escalating counterregulatory hormones (9). In type B NICTH, there is high production of big insulin-like growth factor II (IGF-II) by the tumors. Big IGF-II is formed by defective processing of pro IGF-II to normal-sized IGF-II (7.5 kDa). Normally, most of the IGFs are constructed in ternary complexes consisting of IGF, insulin-like growth factor binding protein-3 (IGFBP-3), and acid labile α-subunit. In this case, the big IGF-II–IGFBP-3 complex could not bind with the acid labile α-subunit, which resulted in a smaller complex that facilitates transport across the capillary membrane and enhances access to target tissues. Big IGF-II inhibits pituitary growth hormone (GH) secretion by binding the IGF-I receptor, which leads to decreased GH and IGFBP-3 (Fig. 1). This is usually found in the early stages of liver disease, which is characterized by overwhelming tissue glucose uptake with severe and persistent hypoglycemia (5, 8, 10, 11, 12, 13, 14).
A flowchart for the understanding of the IGF–GH axis.
Citation: Endocrinology, Diabetes & Metabolism Case Reports 2024, 3; 10.1530/EDM-23-0077
To diagnose NICTH, analyze whether the condition of hypoglycemia fulfilling Whipple’s triad, measurement of serum insulin, C-peptide levels, counter-regulatory hormone, total IGF-II, big IGF-II, and 7.5 kDa IGF-II must be done to divine the type of NICTH (15). In Indonesia, we were unable to test the serum IGF-II level to ensure that hypoglycemia was caused by type B NICTH (10). In our study, most patients presented with jaundice and ascites, which indicated liver decompensation, high Child–Pugh score, and large-sized tumor, suggesting that type A NICTH was the cause of hypoglycemia. Additionally, our patients with refractory hypoglycemia had larger tumor sizes and lower initial blood glucose than patients with controlled hypoglycemia, hence increasing suspicion that type A NICTH was the cause of hypoglycemia. Moreover, although there were 18 patients with initial blood glucose below 50 mg/dL, there were no symptoms of losing consciousness, so the Whipple’s triad was not fulfilled.
In Nigerian patients, the median survival in hepatocellular carcinoma with paraneoplastic manifestation was 36 days. Patients with paraneoplastic syndrome resulting in erythrocytosis tended to have longer survival than similar patients with hypoglycemia and hypercalcemia. Child–Pugh’s score C, ineligibility for active treatment, serum alpha-fetoprotein level > 10 000 ng/mL, and main portal vein thrombosis indicate a poor prognosis (16). In our study, eight patients had portal vein thrombosis, and most of them showed refractory hypoglycemia after treatment was given. Portal vein thrombosis in hepatocellular carcinoma is associated with poor prognosis due to more aggressive tumor behavior, reduced tolerance to treatment due to portal hypertension, and deteriorated liver function reserve (17). Other conditions that can affect the blood glucose level are drug-induced hypoglycemia and liver cirrhosis. There were two patients with type 2 diabetes mellitus. Drug-induced hypoglycemia can be excluded as these patients were not given any hypoglycemic medication before or during hospital admission. In advanced cirrhotic liver, alteration of hepatic glucose metabolism had occured. The hepatic glucose output in response to glucagon is also decreased (6, 16).
Treatment of hypoglycemia in liver cancer is challenging. Patients with liver cancer are more likely to develop recurrent or refractory hypoglycemia. First, standard hypoglycemia treatment must be given. Besides correction of hypoglycemia, specific liver cancer treatment is needed to prevent recurrent hypoglycemia. The therapeutic options are cytoreduction with surgical resection and systemic chemotherapy. However, in advanced disease, cytoreduction is difficult to proceed with, and palliative treatments may be the best choice. In our cases, 17 patients had their hypoglycemia controlled by standard treatment, while one patient showed persistent hypoglycemia and 23 patients showed refractory hypoglycemia despite the provision of standard treatment. No specific treatment was given for the tumor because all the patients were in an advanced stage. The patients were given palliative treatment. In our cases, treatment for hypoglycemia was frequent feeding, dextrose infusion, and steroid injection. Huang and Chang reported that refractory hypoglycemia in advanced hepatocellular carcinoma could be controlled by systemic chemotherapy, and it should be considered when tumor removal surgery cannot be performed (6). Thipaporn et al. reported an effective and inexpensive method to treat persistent hypoglycemia in hepatocellular carcinoma, i.e. corticosteroid administration and frequent high carbohydrate intake. Steroids stimulate gluconeogenesis and increase lipolysis in adipocytes, while frequent high carbohydrate meals may fulfill the high demand for glucose, although sometimes it may not overcome glucose overutilization (14). In addition, steroids also have roles in the inhibition of peripheral glucose intake, suppression of big IGF-2 production, and modulation of the GH–IGF axis. High-dose glucocorticoid therapy, equivalent to prednisone 30–60 mg/day, has an immediate effect on hypoglycemia and is effective in correcting the underlying biochemical dysfunction (14, 18, 19, 20). Glucagon and GH, which are insulin counter-regulatory hormones, can be used as adjunctive (19, 21, 22). Glucagon releases glucose from liver storage to the bloodstream in the event of hypoglycemia. However, this activity decreases in patients with chronic liver disease; thus, continuous glucagon infusion might be favorable as a treatment for hypoglycemia caused by non-islet cell tumor (14, 23). Meanwhile, GH showed an effect in the stimulation of gluconeogenesis and glycogenolysis while increasing IGFBP-3 synthesis. This treatment modality should be used with caution due to the risk of stimulating tumor growth.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the study reported.
Funding statement
This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.
Patient consent
Written informed consent for the publication of the clinical details was obtained from the patients.
Author contribution statement
The authors would like to express their sincerest gratitude to Dr Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia for their continuous support. Kemal Fariz Kalista, Dicky Levenus Tahapary, Saut Horas Nababan, Chynthia Olivia Maurine Jasirwan, Juferdy Kurniawan, Cosmas Rinaldi Adithya Lesmana, Andri Sanityoso Sulaiman, Irsan Hasan, and Rino Gani are the physicians involved in the cases. Kemal Fariz Kalista and Hanum Citra Nur Rahma wrote the manuscript in consultation with Dicky Levenus Tahapary, Cosmas Rinaldi Adithya Lesmana, Irsan Hasan, and Rino Gani. Kemal Fariz Kalista, Dicky Levenus Tahapary, and Cosmas Rinaldi Adithya supervised the writing process of the manuscript. Kemal Fariz Kalista, Hanum Citra Nur Rahma, Dicky Levenus Tahapary, Saut Horas Nababan, Chynthia Olivia Maurine Jasirwan, Juferdy Kurniawan, Cosmas Rinaldi Adithya Lesmana, Andri Sanityoso Sulaiman, Irsan Hasan, and Rino Gani provided feedback and contributed to the final version of the manuscript.
References
- 1↑
Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, Chiang JH, Lui WY, Chu CW, & Lee SD. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002 49 1315–1319.
- 2↑
Saigal S, Nandeesh HP, Malhotra V, & Sarin SK. A case of hepatocellular carcinoma associated with troublesome hypoglycemia: management by cytoreduction using percutaneous ethanol injection. American Journal of Gastroenterology 1998 93 1380–1381. (https://doi.org/10.1111/j.1572-0241.1998.427_h.x)
- 3↑
Sharma M, Reddy DN, & Kiat TC. Refractory hypoglycemia presenting as first manifestation of advanced hepatocellular carcinoma. ACG Case Reports Journal 2014 2 50–52. (https://doi.org/10.14309/crj.2014.82)
- 4↑
Tsai CY, Chou SC, Liu HT, Lin JD, & Lin YC. Persistent hypoglycemia as an early, atypical presentation of hepatocellular carcinoma: a case report and systematic review of the literature. Oncology Letters 2014 8 1810–1814. (https://doi.org/10.3892/ol.2014.2365)
- 5↑
Nikeghbalian S, Bananzadeh A, & Yarmohammadi H. Hypoglycemia, the first presenting sign of hepatocellular carcinoma. Saudi Medical Journal 2006 27 387–388.
- 6↑
Huang JS, & Chang PH. Refractory hypoglycemia controlled by systemic chemotherapy with advanced hepatocellular carcinoma: a case report. Oncology Letters 2016 11 898–900. (https://doi.org/10.3892/ol.2015.3915)
- 7↑
McFadzean AJ, & Yeung RT. Further observation on hypoglycaemia in hepatocellular carcinoma. American Journal of Medicine 1969 47 220–235. (https://doi.org/10.1016/0002-9343(6990148-x)
- 8↑
Forde JJ, Ewelukwa O, Brar T, & Cabrera R. Intractable fasting hypoglycemia as a manifestation of hepatocellular carcinoma. Case Reports in Hepatology 2017 2017 7465025. (https://doi.org/10.1155/2017/7465025)
- 9↑
Marks V, & Teale JD. Tumours producing hypoglycaemia. Diabetes/Metabolism Reviews 1991 7 79–91. (https://doi.org/10.1002/dmr.5610070202)
- 10↑
Yeung RTT. Hypoglycaemia in hepatocellular carcinoma: a review. Hong Kong Medical Journal 1997 3 297–301.
- 11↑
Benn JJ, Firth RG, & Sonksen PH. Metabolic effects of an insulin-like factor causing hypoglycaemia in a patient with a haemangiopericytoma. Clinical Endocrinology 1990 32 769–780. (https://doi.org/10.1111/j.1365-2265.1990.tb00924.x)
- 12↑
Shapiro ET, Bell GI, Polonsky KS, Rubenstein AH, Kew MC, & Tager HS. Tumor hypoglycemia: relationship to high molecular weight insulin-like growth factor-II. Journal of Clinical Investigation 1990 85 1672–1679. (https://doi.org/10.1172/JCI114619)
- 13↑
Gorden P, Hendricks CM, Kahn CR, Megyesi K, & Roth J. Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors. A study of the tumor types. New England Journal of Medicine 1981 305 1452–1455. (https://doi.org/10.1056/NEJM198112103052405)
- 14↑
Thipaporn T, Bubpha P, & Varaphon V. Hepatocellular carcinoma with persistent hypoglycemia: a successful treatment with corticosteroid and frequent high carbohydrate intake. Journal of the Medical Association of Thailand 2005 88 1941–1946.
- 15↑
Bodnar TW, Acevedo MJ, & Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. Journal of Clinical Endocrinology and Metabolism 2014 99 713–722. (https://doi.org/10.1210/jc.2013-3382)
- 16↑
Nduduba DA, Ojo OS, Adetiloye VA, Rotimi O, Durosinmi MA, & Uchegbu LO. The incidence and characteristics of some paraneoplastic syndromes of hepatocellular carcinoma in Nigerian patients. European Journal of Gastroenterology and Hepatology 1999 11 1401–1404. (https://doi.org/10.1097/00042737-199912000-00010)
- 17↑
Liu PH, Huo TI, & Miksad RA. Hepatocellular carcinoma with portal vein tumor involvement: best management strategies. Seminars in Liver Disease 2018 38 242–251. (https://doi.org/10.1055/s-0038-1666805)
- 18↑
Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, & Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in non-islet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 1995 80 2700–2708. (https://doi.org/10.1210/jcem.80.9.7545698)
- 19↑
Perros P, Simpson J, Innes JA, Teale JD, & McKnight JA. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clinical Endocrinology 1996 44 727–731. (https://doi.org/10.1046/j.1365-2265.1996.721542.x)
- 20↑
Teale JD, & Wark G. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clinical Endocrinology 2004 60 457–460. (https://doi.org/10.1111/j.1365-2265.2004.01989.x)
- 21↑
Tietge UJ, Schöfl C, Ocran KW, Wagner S, Böker KH, Brabant G, Zapf J, & Manns MP. Hepatoma with severe non-islet cell tumor hypoglycemia. American Journal of Gastroenterology 1998 93 997–1000. (https://doi.org/10.1111/j.1572-0241.1998.00297.x)
- 22↑
van Wijngaarden P, Janssen JA, & de Man RA. Hepatocellulair carcinoom gecompliceerd door ‘non-islet cell tumour hypoglycaemia’ (niet-insulinoomhypoglykemie) (Hepatocellular carcinoma complicated by non-islet cell tumor hypoglycemia). Nederlands Tijdschrift voor Geneeskunde 2002 146 859–862.
- 23↑
Derrou S, Benabdelfedil Y, El Guendouz F, Ouleghzal H, & Safi S. Severe hypoglycemia complicating hepatocellular carcinoma. International Journal of Case Reports and Images 2020 11 101119Z01SD2020. (https://doi.org/10.5348/101119Z01SD2020CR)